Technical Analysis for AFMD - Affimed Therapeutics B.V.

Grade Last Price % Change Price Change
F 2.72 -9.33% -0.28
AFMD closed down 9.33 percent on Wednesday, November 20, 2024, on 3.52 times normal volume. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
4 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Volume Surge Other 0.00%
Lower Bollinger Band Walk Weakness 0.00%
New 52 Week Low Weakness 0.00%
Wide Bands Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%

   Recent Intraday Alerts

Alert Time
Down 1 ATR about 16 hours ago
Down 5% about 18 hours ago
Fell Below Previous Day's Low about 20 hours ago
New 52 Week Low about 20 hours ago
60 Minute Opening Range Breakdown about 21 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Affimed Therapeutics B.V. Description

Affimed Therapeutics B.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies. Its lead candidate includes AFM13, a natural killer cell bispecific antibody (TandAb) that has completed a Phase I clinical trial for the treatment of certain CD30-positive (CD30+) B- and T-cell malignancies, including hodgkin lymphoma. The company's product candidates also comprise AFM11, a T-cell TandAb for the treatment of certain CD19+ B-cell malignancies, including non-hodgkin lymphoma, acute lymphocytic leukemia, and chronic lymphocytic leukemia; and AFM21, a TandAb program in preclinical development that binds epidermal growth factor receptor variant III for solid tumors, as well as for patients with glioblastoma, hormone refractory prostate cancer, and head and neck cancer. Affimed Therapeutics B.V. has license agreements with Amphivena Therapeutics, Inc. to develop a product candidate for hematologic malignancies; and Xoma Ireland Limited to conduct research on immunoglobulins. The company was founded in 2000 and is headquartered in Heidelberg, Germany.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Solid Tumors Clinical Development Monoclonal Antibodies Lymphoma Immunotherapies Prostate Cancer Blastoma Glioblastoma Epidermal Growth Factor Receptor Hematologic Malignancies Natural Killer Cell Chronic Lymphocytic Leukemia Lymphocytic Leukemia Head And Neck Cancer Tumors Of The Hematopoietic And Lymphoid Tissues CD19 Entospletinib Hodgkin Lymphoma Non Hodgkin Lymphoma

Is AFMD a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 8.95
52 Week Low 2.72
Average Volume 103,657
200-Day Moving Average 4.79
50-Day Moving Average 3.43
20-Day Moving Average 3.44
10-Day Moving Average 3.50
Average True Range 0.25
RSI (14) 28.06
ADX 24.76
+DI 16.07
-DI 30.30
Chandelier Exit (Long, 3 ATRs) 3.28
Chandelier Exit (Short, 3 ATRs) 3.48
Upper Bollinger Bands 4.02
Lower Bollinger Band 2.85
Percent B (%b) -0.11
BandWidth 34.14
MACD Line -0.07
MACD Signal Line 0.01
MACD Histogram -0.0841
Fundamentals Value
Market Cap 406.2 Million
Num Shares 149 Million
EPS -0.85
Price-to-Earnings (P/E) Ratio -3.20
Price-to-Sales 4.05
Price-to-Book 0.99
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.19
Resistance 3 (R3) 3.24 3.13 3.11
Resistance 2 (R2) 3.13 3.01 3.11 3.08
Resistance 1 (R1) 2.93 2.94 2.88 2.88 3.06
Pivot Point 2.82 2.82 2.80 2.80 2.82
Support 1 (S1) 2.62 2.70 2.57 2.57 2.38
Support 2 (S2) 2.51 2.63 2.49 2.36
Support 3 (S3) 2.31 2.51 2.33
Support 4 (S4) 2.26